Breaking Down SG&A Expenses: Zoetis Inc. vs CRISPR Therapeutics AG

A Comparative Analysis of SG&A Expenses: Zoetis Inc. vs. CRISPR Therapeutics AG

In the ever-evolving landscape of biotechnology and pharmaceuticals, understanding the financial dynamics of industry leaders is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Zoetis Inc. and CRISPR Therapeutics AG from 2014 to 2023. Over this period, Zoetis Inc., a global leader in animal health, consistently outpaced CRISPR Therapeutics AG in SG&A spending, reflecting its expansive market reach and operational scale. In 2023, Zoetis's SG&A expenses were approximately 28 times higher than those of CRISPR, highlighting its significant investment in marketing and administrative functions. Meanwhile, CRISPR Therapeutics, a pioneer in gene-editing technology, showed a steady increase in SG&A expenses, peaking in 2021. This trend underscores its growing market presence and strategic investments in innovation. As the biotech sector continues to grow, these financial insights offer a glimpse into the strategic priorities of these industry giants.